HekaBio K.K.

Privately held: no public share price · Japan

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
NK cell therapyCell therapy
Alzheimer's DiseaseNon-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
March 2028 (1)
TroculeucelPhase 1/2Moderate Alzheimer Disease
Est. primary completion 2028-03 · NCT06189963 · CT.gov ↗
What to watch
April 2028 (1)
TroculeucelPhase 2Alzheimer Disease
Est. primary completion 2028-04 · NCT07228078 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.